New injectable gel aims to smooth wrinkles and restore volume

NCT ID NCT07421544

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests Obagi Saypha MagIQ, a hyaluronic acid gel, in 100 adults aged 30-75 with mild-to-moderate facial aging. The gel is injected to treat volume loss, fine lines, and skin laxity. Researchers will measure improvement over 60 days using doctor and patient ratings.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

hyaluronic acid gel (Obagi Saypha MagIQ)

What this could lead to

If it works, this could offer a safe, effective option for reducing fine lines and restoring facial volume without surgery.

What could go wrong

This is a small, early-phase pilot study with no placebo group, so results may not be conclusive. Side effects like swelling or bruising are possible.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for WRINKLE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • West Dermatology Research Center

    San Diego, California, 92121, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact Phone: •••-•••-•••• Email: •••••@•••••